PRF Technologies Ltd. (PRFX)
| Market Cap | 2.61M -33.9% |
| Revenue (ttm) | 17,000 |
| Net Income | -4.84M |
| EPS | -7.47 |
| Shares Out | 868.76K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,104,282 |
| Open | 4.740 |
| Previous Close | 1.370 |
| Day's Range | 2.360 - 5.390 |
| 52-Week Range | 1.280 - 17.950 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 26, 2026 |
About PRFX
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies ... [Read more]
Financial Performance
Financial StatementsNews
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
PRF Technologies stock was up alongside an update on its renewable energy AI platform.
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market dec...
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
PRF Technologies (PRFX) announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release product u...
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with...
PRF Technologies registers to sell 3M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 3M ordinary shares. The company is not selling any shares under…
PRF Technologies announces FDA clearance of OcuRing-K NDA
PRF Technologies (PRFX) announced that the FDA has cleared the company’s investigational new drug application for OcuRing-K, enabling the initiation of a Phase II clinical trial in patients undergoing...
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF'...
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 202...
PRF Technologies signs commercial collaboration agreement with Blade Ranger
PRF Technologies (PRFX) announced a commercial collaboration agreement with Blade Ranger designed to accelerate the commercial expansion of its DeepSolar platform across utility-scale solar portfolios...
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced a commercial collaboration agreement with Blade Ranger Ltd.
PRF Technologies’ DeepSolar announces commercial due diligence engagement
PRF Technologies (PRFX) announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group relating to an operational, utility-scale solar ...
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset in Israel Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale ...
PRF Technologies signs SaaS agreement with Shikun & Binui Energy
PRF Technologies (PRFX) announced the signing of a software-as-a-service, SaaS, agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt, MW, Satu Mare photovoltaic site...
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (Nasdaq: PRFX) (“PRF” or the “Company”), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signin...
PRF Technologies Ltd trading halted, news pending
19:50 EST PRF Technologies (PRFX) Ltd trading halted, news pending
PRF files first patent application for solar plant-level micro-climate modeling
PRF Technologies (PRFX) announced that it has filed a patent application covering proprietary methods for solar plant-level micro-climate modeling designed to significantly improve the accuracy of sol...
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
Patent filing follows acceptance into the NVIDIA Connect Program Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for u...
PainReform changes name to PRF Technologies
PainReform announced its corporate name change to PRF Technologies following shareholder approval at the company’s annual general meeting. The company’s Nasdaq ticker symbol will remain (PRFX).
PainReform Ltd. Changes Name to PRF Technologies Ltd.
Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as ...
PainReform announces safety data supporting development of OcuRing-K platform
PainReform (PRFX) announced safety data supporting the continued development of OcuRing-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery. The development progra...
PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operati...
PainReform’s DeepSolar launches Smart TDD service
PainReform (PRFX) announced that its DeepSolar business unit has launched Smart TDD, a solar Technical Due Diligence service. “The newly enhanced service expands DeepSolar’s audit capabilities to supp...
PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market
New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperforma...
BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week
AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East. TEL AVIV, Israel, Dec...
PainReform completed R&D assessment of LayerBio’s drug-delivery platform
PainReform (PRFX) announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confir...